Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease
Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd.
Summary
To assess the safety and tolerability of single doses of KL002 over 78 weeks in subjects with Parkinson's disease。
Official title: A Phase 1/2a, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KL002, an AAV9 Gene Therapy, in Subjects With Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-12
Completion Date
2029-10
Last Updated
2026-11-10
Healthy Volunteers
No
Conditions
Interventions
Injecting KL002 into the bilateral putamen
KL002 is a recombinant adeno-associated virus (rAAV9) vector carrying TH, GCH1, and AADC genes
Locations (1)
Houston Methodist Hospital
Houston, Texas, United States